215 related articles for article (PubMed ID: 25016811)
1. [Hodgkin lymphoma].
Nagai H
Nihon Rinsho; 2014 Jun; 72(6):1099-103. PubMed ID: 25016811
[TBL] [Abstract][Full Text] [Related]
2. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin (replased/refractory Hodgkin lymphoma and CD30 positive non-Hodgkin lymphoma.
Kitahara H
Gan To Kagaku Ryoho; 2015 May; 42(5):550-2. PubMed ID: 26054088
[No Abstract] [Full Text] [Related]
5. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
9. An update on emerging drugs for Hodgkin lymphoma.
von Tresckow B; Diehl V
Expert Opin Emerg Drugs; 2014 Jun; 19(2):215-24. PubMed ID: 24749769
[TBL] [Abstract][Full Text] [Related]
10. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
Eichenauer DA; Engert A
Expert Rev Hematol; 2017 Sep; 10(9):775-782. PubMed ID: 28665214
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
Pham A; Chen R
Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
Younes A
Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
[TBL] [Abstract][Full Text] [Related]
16. Durable Responses with Brentuximab Vedotin in cHL.
Cancer Discov; 2016 Sep; 6(9):OF1. PubMed ID: 27507410
[TBL] [Abstract][Full Text] [Related]
17. Novel agents in Hodgkin lymphoma.
Moskowitz AJ
Curr Oncol Rep; 2012 Oct; 14(5):419-23. PubMed ID: 22706966
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Cao H; Yamamoto K; Yang LX; Weber R
Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
